Moreover, these functional TCRs could serve as a catalyst in augmenting the spectrum of TCR-T cell therapeutic candidates or soluble bispecific TCRs, aiming for pan-cancer tumors with HLA-A*11:01 restriction. This evidence concerns the gene HLA-A and cancer.